# Endocannabinoids and Polyunsaturated Fatty Acids in Early Schizophrenia: Changes Under Antipsychotics and Treatment Response > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-schizophrenia-early-changes-treatment/ > **Published:** 2026-03-26T11:07:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:08:22-04:00 > **Clinical Summary:** Explore endocannabinoid system schizophrenia changes in early stages and effects of antipsychotic treatment on polyunsaturated fatty acids and biomarkers. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic SchizophreniaEndocannabinoidsPsychosisAnandamidePsychiatric Journal Prostaglandins, leukotrienes, and essential fatty acids Study Type Clinical Study Population Human participants Why This Matters This study provides crucial baseline data on [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) alterations in first-episode schizophrenia, which could inform cannabis counseling for patients with psychotic disorders. The findings suggest the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) is already dysregulated before cannabis exposure, adding important context to discussions about cannabis risk in vulnerable populations. Clinical Summary This case-control study examined 79 antipsychotic-naïve first-episode schizophrenia patients and 78 healthy controls, measuring plasma levels of polyunsaturated fatty acids and endocannabinoids using LC-MS/MS. Results showed lower omega-3 fatty acids (arachidonic, docosapentaenoic, docosahexaenoic) but higher endocannabinoids (anandamide, 2-AG) and related compounds in acute psychosis patients. Thirty-six patients were followed for three months of antipsychotic treatment, though treatment response correlations were not detailed in the available summary. The study establishes that endocannabinoid dysregulation precedes treatment in first-episode psychosis. Dr. Caplan’s Take “This confirms what I see clinically—the endocannabinoid system is already disrupted in early psychosis before any cannabis exposure. It reinforces my approach of thoroughly assessing baseline psychiatric stability before considering any cannabinoid interventions in patients with psychotic risk factors.” Clinical Perspective 🧠 Clinicians should recognize that endocannabinoid system dysfunction may be intrinsic to schizophrenia pathophysiology rather than solely cannabis-induced. This information supports more nuanced counseling about cannabis risks in vulnerable populations, emphasizing that pre-existing system dysregulation may heighten sensitivity to exogenous cannabinoids. Consider baseline psychiatric assessment critical before any cannabis recommendations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Endocannabinoids%20and%20polyunsaturated%20fatty%20acids%20in%20early%20schizophrenia%3A%20Changes...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41825339/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41825339/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Endocannabinoids%20and%20polyunsaturated%20fatty%20acids%20in%20early%20schizophrenia%3A%20Changes...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41825339/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41825339/](https://pubmed.ncbi.nlm.nih.gov/41825339/) Table of Contents - [FAQ](#FAQ)[What biochemical changes occur in patients with first-episode schizophrenia?](#What_biochemical_changes_occur_in_patients_with_first-episode_schizophrenia) - [How do antipsychotic medications affect endocannabinoid and fatty acid levels?](#How_do_antipsychotic_medications_affect_endocannabinoid_and_fatty_acid_levels) - [Can these biomarkers predict treatment response in schizophrenia?](#Can_these_biomarkers_predict_treatment_response_in_schizophrenia) - [Should patients with schizophrenia avoid cannabis use based on elevated endocannabinoids?](#Should_patients_with_schizophrenia_avoid_cannabis_use_based_on_elevated_endocannabinoids) - [Are omega-3 supplements recommended for schizophrenia patients based on these findings?](#Are_omega-3_supplements_recommended_for_schizophrenia_patients_based_on_these_findings) - [Related](#Related) ## FAQ #### What biochemical changes occur in patients with first-episode schizophrenia? First-episode schizophrenia patients show decreased levels of key polyunsaturated fatty acids (arachidonic, docosapentaenoic, and docosahexaenoic acids) but elevated endocannabinoids including anandamide and 2-arachidonoyl glycerol. These changes suggest significant dysregulation in both fatty acid metabolism and endocannabinoid system function during the acute phase of illness. #### How do antipsychotic medications affect endocannabinoid and fatty acid levels? After three months of antipsychotic treatment, patients showed changes in their biochemical profiles, though the study summary doesn’t specify the exact nature of these changes. This suggests that antipsychotic therapy may help normalize some of the metabolic dysregulation seen in untreated first-episode schizophrenia patients. #### Can these biomarkers predict treatment response in schizophrenia? The study examined associations between endocannabinoid/fatty acid levels and treatment response, indicating potential predictive value. However, given the “monitored relevance” classification, these biomarkers require further validation before clinical implementation for predicting treatment outcomes. #### Should patients with schizophrenia avoid cannabis use based on elevated endocannabinoids? While the study shows elevated endocannabinoid levels in first-episode schizophrenia, this doesn’t directly inform [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) recommendations. The elevated endocannabinoids may represent a compensatory response, and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) decisions should be based on established clinical evidence showing increased [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) with cannabis consumption. #### Are omega-3 supplements recommended for schizophrenia patients based on these findings? The decreased levels of docosahexaenoic and docosapentaenoic acids (omega-3 fatty acids) in first-episode patients suggest potential benefit from supplementation. However, this remains an area requiring further clinical evidence, and any supplementation should be discussed with treating physicians as part of comprehensive treatment planning. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Endocannabinoids and polyunsaturated fatty acids in early schizophrenia: Changes under antipsychotics and association with the response to treatment.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41825339/”, “about”: “prostaglandins leukotrienes essential fatty acids clinical”, “isPartOf”: “Prostaglandins, leukotrienes, and essential fatty acids”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis-Induced Psychosis and Psychotic Disorders: Key Evidence](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) Review key evidence on [cannabis-induced psychosis](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) and its relation to psychotic disorders, providing context for endocannabinoid system research in schizophrenia. [Read More](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) [The Effect of Cannabis Use on Positive and Negative Affect in Youth](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) Explore how cannabis use influences emotional states in youth, relevant for understanding cannabis risks in vulnerable populations with psychiatric conditions. [Explore Article](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) An evidence-based review of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments in Europe, offering insights into managing cannabis-related psychiatric risks. [Learn More](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).